Spero Therapeutics: Remodeling Antibiotics
This article was originally published in Start Up
Executive Summary
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
You may also be interested in...
IPO Update: Biopharma Firms Give Thanks For Receptive US Investors
Six biopharma firms went public in the US in November during the three weeks leading up to Thanksgiving, raising $539.5m and counting. With 39 IPOs so far this year, 2017 has had nine more first-time offerings than 2016 with five more weeks to go.
Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.